Opinion
Video
The Role of PSA Doubling Time in Risk Assessment
Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.
- Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment?
- At what PSA doubling time thresholds do treatment recommendations change?
- How reliable is PSA doubling as a biomarker versus imaging or other tests?
Related Videos
Related Content
